Multiple Studies on Agendia’s MammaPrint and BluePrint Tests to Be Featured at ASCO Annual Meeting

Publication Name: Press Release

IRVINE, CA and AMSTERDAM, THE NETHERLANDS, May 22, 2014– New research involving Agendia’s genomic tests MammaPrint®, BluePrint®, TargetPrint® and TheraPrint®, as well as its ColoPrint® Colon Cancer Genomic Profile, will be reported at the 2014 annual meeting of the American Society of Clinical Oncology (ASCO), May 30 – June 3 at McCormick Place in Chicago, Ill. The new data encompasses seven scientific posters and one oral presentation at the conference.

Genomic tests are part of the revolution in personalized medicine, a field in which Agendia is a leader. Genomic tests examine the activity of groups of genes within a cancer tumor, to provide a more comprehensive view of the cancer biology and treatment options.

The 70-gene MammaPrint test provides definitive High Risk or Low Risk information about breast cancer recurrence, with no ambiguous “intermediate” results. The 80-gene BluePrint assay then identifies the molecular subtype, the predominant genomic pathway driving the cancer, and predicts tumor response to targeted therapies before and after surgery. These tests are the only widely available assays that provide molecular subtyping to guide breast cancer treatment decisions. The four molecular subtypes are known as Luminal-type A, Luminal-type B, Basal-type and HER2-type.

“Agendia will have an especially strong presence at this year’s ASCO meeting,” said oncologist Neil Barth, M.D., the company’s Chief Medical Officer. “The multiple presentations on our assays for breast cancer and colon cancer, as well as the clinical trials in which MammaPrint and BluePrint play an essential role, reflect the increasingly widespread adoption of our molecular diagnostic tests.”

To learn more about the Agendia tests, ASCO attendees can visit Booth #16025. To attend any of the eight ASCO presentations on genomic tests from Agendia, consult the following (all times are Central Daylight Time):

Breast cancer

POSTER PRESENTATION: MINT: Multi-Institutional Neo-Adjuvant Therapy, MammaPrint Project (Abstract # TPS1137)
Lead Author: Charles E. Cox, M.D.; Breast Health Program, University of South Florida College of Medicine
Session Title: Breast Cancer – Triple-Negative/Cytotoxics/Local Therapy
Date: Monday, June 2, 2014
Time: 8:00 a.m. – 11:45 a.m.
Location: S Hall A2
Poster Board #: 228B

POSTER PRESENTATION: Chemosensitivity and endocrine sensitivity predicted by MammaPrint and BluePrint in the Neo-adjuvant Breast Registry Symphony Trial (NBRST) (Abstract #1078)
Lead Author: Pat W. Whitworth, M.D., Nashville Breast Center
Session Title: Breast Cancer – Triple-Negative/Cytotoxics/Local Therapy
Date: Monday, June 2, 2014
Time: 8:00 a.m. – 11:45 a.m.Location: S Hall A2
Poster Board #: 171

POSTER PRESENTATION: Genomic profiling of breast cancer in African-American women (Abstract #11067)
Lead Author: Racquel Nunes, M.D., Washington Cancer Institute
Session Title: Tumor biology
Date: Saturday, May 31, 2014
Time: 1:15 p.m. – 5:00 p.m.
Location: S Hall A2
Poster Board #: 349

POSTER HIGHLIGHTS PRESENTATION: Biomarker panel (TheraPrint) analyzed as predictor of response to neo-adjuvant chemotherapy in patients with locally advanced breast cancer (Abstract #1026)
Lead Author: Peter D. Beitsch, M.D., FACS, Medical City Dallas Hospital
Session Title: Breast Cancer – Triple-Negative/Cytotoxics/Local Therapy
Date: Monday, June 2, 2014
Time: 1:15 p.m. – 4:15 p.m.
Location: E354b
Poster Board #: 19

POSTER PRESENTATION: Comparison of test results and clinical outcomes of patients assessed with both MammaPrint and Oncotype DX with pathologic variables: an independent study (Abstract #550)
Lead Author: David J. Dabbs, M.D., Chief of Pathology, Magee-Womens Hospital, University of Pittsburgh Medical Center
Session Title: Breast Cancer – HER2/ER Date: Monday, June 2, 2014
Time: 8:00 a.m. – 11:45 a.m.
Location: S Hall A2
Poster Board #: 14

Colon cancer

ORAL PRESENTATION: Colorectal cancer subtyping consortium (CRCSC) identifies consensus of molecular subtypes (Abstract #3511)
Lead Author: Rodrigo Dienstmann, Ph.D., M.D., Research Scientist, Sage Bionetworks
Session Title: Colorectal Cancer: Not Just One Disease
Session Type: Clinical Science Symposium
Date: Tuesday, June 3, 2014
Time: 10:21 a.m. – 10:33 a.m. (Session time: 9:45 a.m. – 11:15 a.m.)
Location: S406

POSTER PRESENTATION: Molecular subtyping of colorectal cancer identifies patients with a mesenchymal tumor type who might benefit from TGF-beta inhibition (Abstract #3618)
Lead Author: Ramon Salazar, M.D., Ph.D., Catalan Institute of Oncology, L´Hospitalet de Llobregat (Barcelona, Spain)
Session Title: Gastrointestinal (Colorectal) Cancer
Date: Saturday, May 31, 2014
Time: 8:00 a.m. – 11:45 a.m.
Location: S Hall A2
Poster Board #: 81

POSTER PRESENTATION: Comparison of ColoPrint risk classification with clinical risk in the prospective PARSC trial (Abstract #3562)
Lead Author: Ramon Salazar, M.D., Ph.D., Catalan Institute of Oncology, L´Hospitalet de Llobregat (Barcelona, Spain)
Session Title: Gastrointestinal (Colorectal) Cancer
Date: Saturday, May 31, 2014
Time: 8:00 a.m. – 11:45 a.m.
Location: S Hall A2
Poster Board #: 25

Resources for further reference

* RASTER prospective outcome study and press release

* MammaPrint can accurately stratify breast cancer risk for up to 25 years after first diagnosis: study and press release

* Molecular subtyping study

About Agendia

Agendia is a leading molecular diagnostics company that develops and markets FFPE-based genomic diagnostic products, which help support physicians with their complex treatment decisions. Agendia’s tests were developed using an unbiased gene selection by analyzing the complete human genome. This includes MammaPrint as well as BluePrint, a molecular subtyping assay that provides deeper insight leading to more clinically actionable biology, TheraPrint, and TargetPrint, an ER/PR/HER2 expression assay. MammaPrint is the only breast cancer recurrence assay backed by peer-reviewed, prospective outcome data. These tests can help physicians assess a patient’s individual risk for metastasis, which patients may benefit from chemo, hormonal, or combination therapy, and which patients may not require these treatments and can instead be treated with other, less arduous and less costly methods.

In addition, Agendia has a pipeline of other genomic products in development. The company collaborates with pharmaceutical companies, leading cancer centers and academic groups to develop companion diagnostic tests in the area of oncology and is a critical partner in the ISPY-2 and the MINDACT trials. For more information, visit www.agendia.com.

Contact:

Liz Dowling (Medical & Consumer Media)
Dowling & Dennis Public Relations
415-388-2794
Liz@DowlingDennis.net

Matt Clawson (Financial Media)
Pure Communications
949-370-8500
Matt@purecommunications.com